AI-Powered Longevity Science — One Gene to Reverse Aging? | Daniel Ives PhD
In this episode, Dr. Robert Lovekin talks with Dr. Daniel Ives, founder of Shift Bioscience, about moving from hypothesis‑driven aging research to data‑driven, AI‑powered approaches. Ives explains how his early focus on mitochondrial DNA mutations as the primary cause of aging was disproven by epigenetic clock data, prompting a pivot to using single‑cell aging clocks and virtual cell models to run thousands of in‑silico experiments. The discussion highlights the discovery of single genes that can rejuvenate cells without inducing pluripotency and the translation of these findings into targets for conditions like fibrosis and age‑related hearing loss.
The Longevity Economy Is Built for the Rich
The episode examines the $6 trillion "longevity economy"—the booming market built around anti‑aging and wellness innovations—and highlights how its benefits are disproportionately accessible to the wealthy. It outlines macro trends driving investment in longevity, critiques the uneven distribution of cutting‑edge therapies,...
AI in Oncology Takes Off, Tackling HIV and Liver Disease, Pharma’s Recent Gains
The episode recaps highlights from the AACR conference, emphasizing that AI is moving from pre‑clinical research into clinical oncology, but adoption is hampered by low digital pathology uptake (under 10% of U.S. labs), trust issues, and infrastructure costs. It then...
How AI and Robotics Designed New Cancer Therapies
In this episode, Angus Sinclair, CSO of LabGenius Therapeutics, explains how their AI‑driven AVA platform combines high‑throughput cell‑based assays with machine learning to design non‑intuitive protein therapeutics, specifically T‑cell engagers for solid tumors. He details the challenges of targeting antigens...
Scaling Bio 008: Serif Biomedicines' Jake Rubens on Turning Modified DNA Into a New Class of Medicine
In this episode, Jake Rubens of Serif Biomedicines explains how the company is turning DNA into a new class of medicines by using chemically modified DNA and a protein co‑factor to overcome DNA’s historic immunogenicity and delivery challenges. He contrasts...
Cancer Breakthrough Suppressed?
In this episode, Dr. Peter McCullough discusses a human observational study conducted by the Wellness Company on an off‑label combination of ivermectin and benazole for various solid‑tumor cancers. Among roughly 200 participants, 84% reported positive outcomes, with 48% experiencing tumor regression...
Major Antineoplastic Mechanisms of Combination Ivermectin-Mebendazole
In this episode of American Sunrise, chief scientific officer Dr. Peter McCullough discusses a new wellness‑company study showing that the antiparasitic drugs ivermectin and mebendazole, when used alongside standard cancer therapies, yielded an 84% positive net clinical benefit in over 200...
The Real Drivers of GLP-1 Growth
In this episode, Terrence Flynn, Morgan Stanley’s Head of U.S. Pharma and Biotech Research, outlines the next phase of growth for GLP‑1 obesity medicines, estimating the market could peak at about $190 billion globally. He highlights five key drivers: the shift...
![[Emergency Pod] Peptides - Part 1 with Sunita Mohanty of Ultralight](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://megaphone.imgix.net/podcasts/d0db1eda-2c6f-11ef-958d-9fb4aba9c1ce/image/0bfc12f76c8a92fdb53253e1c884033d.jpg?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress)
[Emergency Pod] Peptides - Part 1 with Sunita Mohanty of Ultralight
In this episode of Lifers, host Christina Farr talks with Sunita Mohanty, CEO and co‑founder of Ultralight, about the booming interest in peptide therapies for wellness and longevity. Sunita explains that while peptides are gaining popularity—driven by anecdotal success, recent...
Why Genetic Diagnoses Take So Long for Kids
In this brief episode, host Catherine interviews the CEO of GeneDX about the stark delay—averaging five years—in diagnosing children with genetic diseases, despite the availability of rapid whole exome and genome sequencing that can deliver results in days. She explains...
DDW Highlights: 14 April 2026
In this episode, Bruno Quinney highlights three major developments: the discovery of a new recessive neurodevelopmental disorder linked to mutations in the non‑coding gene RNU4‑2, a first‑in‑human trial of personalized CAR‑T cell therapies for hard‑to‑treat solid tumors in children, and...
Can a Transplant Cure Aging? | Catherine Baucom MD PhD
In this episode, Dr. Robert Lovekin talks with Dr. Catherine Baucom, chief medical officer of MitoSense, and veteran health expert Van about mitochondrial organelle transplantation—a novel therapy that injects healthy mitochondria from young donors into patients to repair damaged cells....
The Psychedelic Revolution
The episode explores the emerging field of psychedelic therapy, highlighting its potential to treat treatment‑resistant mental health conditions with a few supervised dosing sessions rather than daily medication. Guests Dr. Will Vanderveer and Keith Kurlander explain how the approach combines...
One Reporter’s Life-Altering Psychedelic Trip
In this episode of The Daily, host Natalie Kittrow discusses ibogaine—a powerful, illegal psychedelic—with veteran New York Times reporter Robert Draper, who recounts his recent ten‑hour treatment in Tijuana, Mexico. Draper explains ibogaine’s origins, its potential to trigger neuroplasticity and...
Drugs From a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
In this episode of Touching Base, the GEN editors discuss how AI agents are accelerating scientific discovery, highlighting startups like Latent Labs that can design therapeutic antibodies from a simple text prompt and LabOS, an extended‑reality platform that integrates AI,...
Why Diverse Thinking Builds Better AI | Biotech Leadership with Fernando Bardella
In this episode, host Steve Swan talks with global biotech executive Dr. Fernando Bardellá about how diverse cultural and disciplinary backgrounds drive better AI and technology strategies in life sciences. Bardellá shares insights from moving from France to Boston, highlighting...
Intercepting Cancer When DNA Surveillance Fails
In this episode, Daniel Levine talks with Marina Udier, CEO of Newscom, about the company’s innovative cancer‑interception strategy that targets tumors arising from microsatellite instability (MSI) and deficient DNA mismatch repair, such as those seen in Lynch syndrome. Udier explains...
DDW Highlights: 7 April 2026
In this episode, Bruno Quinney highlights several breakthrough developments in drug discovery: the FDA’s accelerated approval of Avlaya, the first brain‑penetrant biologic for Hunter syndrome; Eli Lilly’s $2 billion acquisition of Centessa Pharmaceuticals to expand its orexin‑based sleep‑wake therapies; Mount Sinai’s AI‑powered...
The Longevity Nerve: The Missing Link in Stress, Aging & Brain Health | Elisabetta Burchi MD
In this episode, Dr. Elisabetta Burchi explains how the vagus nerve serves as a central hub linking the brain to the heart, gut, immune system, and overall longevity. She outlines the anatomy and function of the vagus within the parasympathetic...
Decentralized Trials That Scale Globally Without Compliance Risks - with Emma Vitalini of Amgen
In this episode, Emma Vitalini, Head of Global Digital Health Technology Innovation at Amgen, discusses how AI and decentralized trial technologies are transforming patient recruitment, screening, and global trial accessibility. She explains that AI can rapidly parse unstructured genomic and...
Dr Sorcha O'Connor: The PsilOCD Study Investigating Low-Dose Psilocybin for OCD (#532)
In this episode, host Stuart Ralph talks with Dr. Saoirse O'Connor, a neuroscientist who led the PsilOCD study—the first controlled European trial of low‑dose psilocybin for obsessive‑compulsive disorder. The conversation covers the science of psilocybin, the study design (a 10 mg...
How Drug Discovery Is Tackling Global Health Challenges
In this DDW podcast episode, host Bruno Quinney discusses two recent DDW articles: one on the urgent need to combat antimicrobial resistance (AMR) with insights from Professor Janet Hemingway, and another on the rapid expansion of mRNA therapeutics. Hemingway highlights...
28 Months Later: FDA Still Hasn't Revealed Rick Bright and Janet Woodcock's Communications
The episode delves into the controversy surrounding the FDA’s handling of hydroxychloroquine during the COVID‑19 pandemic, focusing on whistleblower Dr. Rick Bright’s claims that Dr. Janet Woodcock pressured him to pursue an Emergency Use Authorization (EUA) rather than an expanded‑access protocol....
The War on Peptides — Why Retatrutide Is at the Center
In this episode of Business Game Changers, host Sarah Westall and Dr. Diane Kayser discuss the rapidly evolving peptide market, focusing on the upcoming weight‑loss peptide retatrutide (also called Reditrutide). They explain how big‑pharma is moving to control peptide supplements,...
Agentic AI, Virtual Cell, LNP Vaccine Boosters, Engineered Organs, and Mergers
In this episode of Touching Base, the Gen editorial team discusses the latest advances in AI for life sciences, including NVIDIA’s GTC announcements on agentic AI, the deployment of 3,500 GPUs by Roche, and the emergence of open‑source autonomous agents...
Verdesian Life Sciences’ Clare Doyle on Bio-Tech Solutions in 2026
Clare Doyle, chief scientist at Verdesian Life Sciences, outlined the company’s 2026 bio‑tech roadmap, emphasizing engineered nutrient‑delivery platforms and AI‑driven field management. She highlighted partnerships with agri‑tech startups to accelerate gene‑edited microbial solutions and noted upcoming regulatory filings for next‑generation...
DDW Highlights: 26 March 2026
In this episode, Bruno Quinney highlights three breakthrough studies: Edinburgh researchers engineered E. coli to convert PET plastic waste into the Parkinson's drug L‑DOPA, offering a sustainable route to a vital medication; scientists identified the enzyme DHX8 as a key...
A Class Action Suits Moves RICO From Mobsters to Medicine
In this episode, attorney Harrison James explains how the Racketeer Influenced and Corrupt Organizations Act (RICO), originally aimed at organized crime, is being used in a landmark civil class action against Takeda Pharmaceuticals and Eli Lilly over the diabetes drug Actos....
Outsmarting Resistance with Rhythm
In this episode, Immuneering CEO Ben Zeskin explains the company’s novel “deep cyclic inhibition” dosing strategy, which delivers intense, short‑duration MEK inhibition pulses instead of continuous suppression. By restoring the natural intermittent signaling rhythm in healthy cells while repeatedly ambushing...
They’ve Revived Dead Brains. And Now We Might Finally Get Some Cures
In this episode, host Volime Vesela, a physician‑scientist and CEO of Bexerg, discusses his startup’s groundbreaking work reviving dead human brains to create an intact human brain lab for drug testing. He explains how his Croatian co‑founder, Dr. Josep "Joe"...
DDW Highlights: 17 March 2026
In this DDW Highlights episode, Bruno Quinney reviews four major stories: a Mayo Clinic study linking the Parkinson's protein alpha‑synuclein to dramatically faster Alzheimer’s progression in women; a Texas A&M‑funded project testing extracellular vesicle (EV) therapy to modulate microglia and...
#384 - Special Episode — Obicetrapib: The CETP Inhibitor with Cardiovascular Benefits and Potential Alzheimer's Prevention
In this special episode, host Peter Atiyah dives deep into obicetrapib, a CETP inhibitor that lowers LDL‑C and ApoB while raising HDL‑C, and examines its renewed promise in cardiovascular disease and potential Alzheimer’s prevention, especially for APOE‑E4 carriers. He outlines...
Chris Bradley: Better Science for Longevity
In this episode, host Rizim Tom chats with Chris Bradley of MatterBio about the science of longevity, focusing on how genomic damage drives the hallmarks of aging. Bradley explains that while cells constantly renew, DNA damage from internal sources like...
Inside The Race To Reboot Human Cells - EP 60 Nabiha Saklayen
In this episode, host Ashley Vance talks with Nabiha Saklayen, co‑founder and CEO of Celino, about induced pluripotent stem cells (iPSCs) and their rapid evolution from a Nobel‑winning discovery to emerging therapies. They discuss how iPSCs can be reprogrammed from...
Editing Away Autoimmunity at the HLA Source
In this episode, Daniel Levine interviews Richard Freed, CEO of Rheumagen, about the pivotal role of HLA genes in autoimmune diseases and the company’s innovative gene‑editing approach to cure them. Freed explains how a single amino‑acid change at a conserved...
The Skin We’re In: Microfluidics, Bubbles, and Healthcare Solutions with Prof. David Fernández Rivas
In this episode, Professor David Fernández‑Rivas discusses the role of engineers as problem‑solvers and the necessity of interdisciplinary collaboration, especially between physics, chemistry, and bioengineering. He explains microfluidics—manipulating fluids at the micrometer scale—and its parallels with microelectronics, then delves into...
Why Asia Is the Emerging Epicenter for Global Biopharmaceutical Progress
In this episode, Daniel Levine talks with Feng Nying Zhang, a partner at McKinsey Shanghai, about Asia’s rapid rise as a global hub for biopharmaceutical innovation, highlighted by a McKinsey report showing the region’s share of innovative drug pipelines jumping...
DDW Highlights: 3 March 2026
In this episode, Bruno Quinney highlights four major developments: a long‑acting injectable HIV regimen (cabotegravir + rilpivirine) that cut virological failure risk by nearly half versus daily oral therapy; SolasCure’s ORES wound gel, which accelerated debridement 22‑fold and healing seven‑fold in chronic...
Where Life Science Meets Litigation
In this episode of Inside Biotech, host Karish Manchugani chats with Tim Dabrowski, a Berkeley‑trained patent attorney at Mintz, about his unconventional path from a physiology degree to biotech IP law. Tim explains how his scientific background informs his work...
Mike White: Academia and Genomics in the 21st Century
In a recent Unsupervised Learning episode, Razib Khan interviews Washington University genetics professor Mike White about his lab’s work on the biophysical architecture of regulatory DNA. White’s interdisciplinary approach combines functional genomics, synthetic biology, computational biology and deep‑learning to predict...
AI for Scientists, FDA Reverses Course, and Advances in Cancer Therapeutics
The episode covers three main business stories: Tamarin Bio’s $13.6M Series A to build an AI model‑coordination platform that makes tools like AlphaFold accessible to wet‑lab biologists; the FDA’s reversal on Moderna’s mRNA‑1010 seasonal flu vaccine, spurring a modest stock...
Drug Dealin Ep. 9: Using AI to Find Novel Treatment Options
In Episode 9 of Drug Dealin, hosts Kenny and Shibu demonstrate how patients can use publicly available tools like ClinicalTrials.gov and AI language models to uncover novel treatment options, focusing on a hypothetical Parkinson’s disease case inspired by a TV...
Reprogramming Cancer From Within
In this episode, Dr. Aaron Vinnie shares his journey from a leukemia survivor to a Columbia University hematology‑oncology researcher, advocating a shift from traditional cytotoxic chemotherapy to precision strategies that rewire malignant blood cells. He explains how hematologic cancers stem...
DDW Highlights: 17 February 2026
In this 16‑minute DDW Highlights episode, host Bruno Quinney recaps five major drug‑discovery stories from the past week, focusing on a breakthrough study linking specific biomarkers to improved cancer survival rates and the launch of a multinational consortium tackling chronic...
Novartis CEO Vasant Narasimhan on Transforming a 250-Year-Old Company
In this episode, a16z partner Jorge Conde interviews Novartis CEO Vasant Narasimhan about reshaping the 250‑year‑old conglomerate into a focused medicines company, a move he estimates will unlock $180 billion of value. Narasimhan outlines Novartis’s three platform pillars—cell and gene therapies,...
Women in Science, Robotics, Automation, SLAS, and Lilly Updates
The episode opens with a celebration of Women in Science Day, highlighting the historic origin of the term “scientist” and the push for greater female leadership in biotech. Medra CEO Michelle Lee discusses how the company is merging robotics with...
🔬Beyond AlphaFold: How Boltz Is Open-Sourcing the Future of Drug Discovery
In this episode, Gabriele Corso and Jeremy Wohlwend discuss how structural biology has moved beyond AlphaFold's single‑chain predictions toward modeling complex interactions and generative protein design with their open‑source Boltz suite (Boltz‑1, Boltz‑2, and BoltzGen). They explain that evolutionary co‑variation...
A One Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer
The episode explores EnGene's experimental gene therapy, detalimogene, for treating non‑muscle invasive bladder cancer, a condition affecting half a million new patients annually. Ron Cooper, EnGene's CEO, explains how the therapy uses a non‑viral vector to deliver a dual payload...
DDW Highlights: 10 February 2026
In this 15‑minute episode, DDW host Bruno Quinney recaps five major stories from the past week, highlighting breakthrough cancer therapies that promise greater efficacy and safety, and new research aimed at enhancing brain function in Alzheimer’s patients. He also touches...
Reprogramming T Cells to Cross the Brain’s Border
In this episode, host and guest Michael Roberts, co‑founder and CEO of Adaptin Bio, discuss the difficulty of delivering biologic therapies across the blood‑brain barrier for glioblastoma patients. Roberts explains Adaptin’s platform, which reprograms a patient’s own T cells to...